How were Affymetrix's earnings last quarter?

Affymetrix Inc (NASDAQ:AFFX) announced its quarterly earnings data on Wednesday, February, 17th. The scientific and technical instruments company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.02. The scientific and technical instruments company earned $95.60 million during the quarter, compared to analyst estimates of $93.29 million. During the same period last year, the company posted $0.09 EPS.

What other stocks do shareholders of Affymetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affymetrix investors own include Orchid Island Capital (ORC) , XOMA (xoma) , Alnylam Pharmaceuticals (ALNY) , Ascent Solar Technologies (ASTI) , NXP Semiconductors (NXPI) , ACADIA Pharmaceuticals (ACAD) , Hugoton Royalty Trust (HGT) , Intel (INTC) , NVIDIA (NVDA) and Applied Materials (AMAT) .

NASDAQ:AFFX

Affymetrix (AFFX) Stock Price, News & Analysis

→ Next-Gen AI is Creating Millionaires Right Now (From InvestorPlace) (Ad)

Free AFFX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $14.01
▼
$14.01
50-Day Range: N/A
52-Week Range: $8.28
▼
$16.15

Volume: N/A
Average Volume: 3.49 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Affymetrix alerts:

Ad InvestorPlace

Next-Gen AI is Creating Millionaires Right Now

I predict massive unemployment is coming. 800 million could lose their jobs, according to a McKinsey study, and 70% of all existing occupations could see a pay cut because of job elimination, according to Wired magazine.

Here’s what I’m recommending now (includes 2 stock tickers).

About Affymetrix Stock (NASDAQ:AFFX)

Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.

Ad InvestorPlace

Next-Gen AI is Creating Millionaires Right Now

Here’s what I’m recommending now (includes 2 stock tickers).

AFFX Stock News Headlines

April 4, 2023 | thestreet.com

Affymetrix Reaches New 52-Week High (AFFX)

February 21, 2023 | thestreet.com

Thermo Fisher Can Afford More Deals After Affymetrix Buy

June 26, 2024 | InvestorPlace (Ad)

Next-Gen AI is Creating Millionaires Right Now

January 2, 2023 | thestreet.com

Affymetrix (AFFX) Stock Drops After Rejecting Origin Technologies Takeover Bid

March 1, 2022 | thestreet.com

'Mad Money' Lightning Round: A Group to Avoid

January 20, 2022 | thestreet.com

Thermos Fisher (TMO) Stock Closed Up on Affymetrix Acquisition

See More Headlines

Receive AFFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affymetrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/17/2016
Today: 6/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NASDAQ:AFFX
CUSIP: 00826T10
CIK: 913077
Web: www.affymetrix.com
Phone: +1-408-7315000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Competitors

View All Competitors

AFFX Stock Analysis - Frequently Asked Questions

How were Affymetrix's earnings last quarter?: Affymetrix Inc (NASDAQ:AFFX) announced its quarterly earnings data on Wednesday, February, 17th. The scientific and technical instruments company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.02. The scientific and technical instruments company earned $95.60 million during the quarter, compared to analyst estimates of $93.29 million. During the same period last year, the company posted $0.09 EPS.
What other stocks do shareholders of Affymetrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Affymetrix investors own include Orchid Island Capital (ORC), XOMA (xoma), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), NXP Semiconductors (NXPI), ACADIA Pharmaceuticals (ACAD), Hugoton Royalty Trust (HGT), Intel (INTC), NVIDIA (NVDA) and Applied Materials (AMAT).